38:["$","div",null,{"className":"overflow-x-auto","children":["$","table",null,{"style":{"width":"100%","borderCollapse":"collapse","marginBottom":"1em"},"children":[["$","thead",null,{"children":["$","tr",null,{"children":[["$","th",null,{"style":"$11:props:children:1:props:children:props:children:0:props:children:props:children:0:props:style","children":"Drug/Class"}],["$","th",null,{"style":"$11:props:children:1:props:children:props:children:0:props:children:props:children:0:props:style","children":"Trial (Year)"}],["$","th",null,{"style":"$11:props:children:1:props:children:props:children:0:props:children:props:children:0:props:style","children":"Mortality Reduction (%)"}],["$","th",null,{"style":"$11:props:children:1:props:children:props:children:0:props:children:props:children:0:props:style","children":"Inclusion Criteria"}]]}]}],["$","tbody",null,{"children":[["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"BB Carvedilol"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"COPERNICUS, 2001"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"38%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA III/IV, LVEF < 25%, on ACEI + diuretic"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"Metoprolol succinate"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"MERIT-HF, 1999"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"34%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA II-IV, LVEF < 40%, on ACE + diuretic + digitalis"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"Bisoprolol"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"CIBIS-II, 1999"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"32%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA III/IV, LVEF <35%, on ACEI + diuretic"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"MRA Eplerenone"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"EMPHASIS-HF, 2011"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"37%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA II, LVEF < 30%, on ACE (or ARB) + BB"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"Spironolactone"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"RALES, 1999"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"30%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA III/IV, LVEF <35%, on ACEI + diuretic, Cr<2.5"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"ARNI Sacubitril/Valsartan"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"PARADIGM-HF, 2014"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"16%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA II-IV, LVEF <35%, on ACE (or ARB) + diuretic, eGFR > 30, SBP > 100"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"ACE Captopril"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"SAVE, 1992"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"19%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"21-79 y.o., recent MI (within 3-16 days), LVEF < 40%"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"Lisinopril"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"ATLAS, 1999"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"12%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA II-IV, LVEF <35%, on diuretic + digitalis"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"Enalapril"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"SOLVD-Treatment, 1991"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"11%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA II-III LVEF<35%"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"ARB Losartan"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"Phase III-Int'l, 2000"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"51%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA II-IV, LVEF <35%, on ACE (or ARB) + BB"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"Valsartan"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"Val-HeFT, 2001"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"13%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA II-IV, LVEF <40%, on ACE + diuretic + digitalis"}]]}],["$","tr",null,{"children":[["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":["$","strong",null,{"children":"SGLT2 Empagliflozin"}]}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"EMPEROR-Reduced, 2020"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"8%"}],["$","td",null,{"style":"$11:props:children:1:props:children:props:children:1:props:children:0:props:children:0:props:style","children":"NYHA II-IV, LVEF < 40%, on ACE (or ARB, ARNI) + BB + MRA"}]]}]]}]]}]}]

Internal Medicine